Company news

Q32 Bio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting

March 14, 2023

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

March 8, 2023

Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer

March 8, 2023

Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

March 1, 2023

Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting

February 21, 2023

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

January 3, 2023

Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

November 9, 2022

Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting

October 26, 2022

Homology Medicines to Participate at Upcoming Conferences

October 5, 2022

Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer

September 5, 2022

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

August 14, 2022

Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

August 10, 2022

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

July 4, 2022

Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

June 28, 2022

Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU

June 12, 2022

Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression

May 17, 2022

Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights

May 15, 2022

Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting

May 1, 2022

Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President

April 20, 2022

Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 22, 2022

Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica

March 9, 2022

Homology Medicines to Participate in Upcoming Investor Conferences

March 2, 2022

Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

February 17, 2022

Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting

February 9, 2022

Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights

November 14, 2021

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

October 20, 2021

Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting

October 19, 2021

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)

October 17, 2021

Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU

October 11, 2021

Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights

August 11, 2021

Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

August 4, 2021

Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting

May 12, 2021

Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights

May 5, 2021

Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting

May 2, 2021

Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model

April 27, 2021

Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting

April 13, 2021

Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer

April 11, 2021

Homology Medicines Announces Pricing of Public Offering of Common Stock

April 6, 2021

Homology Medicines Announces Proposed Public Offering of Common Stock

April 5, 2021

Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

March 10, 2021

Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform

February 28, 2021

Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences

February 24, 2021

Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

February 7, 2021

Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)

January 5, 2021

Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights

November 8, 2020

Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.

November 8, 2020

Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU

November 5, 2020

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

November 4, 2020

Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome

October 21, 2020

Homology Medicines to Participate in Upcoming Conferences

September 17, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.